PatientsVille.com Logo

MUSCLE SPASMS and Prednisone

PatientsVille

MUSCLE SPASMS Symptoms and Causes

Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back.

Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow.

There are three types of angina:

  • Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help.
  • Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon.
  • Variant angina is rare. It happens when you are resting. Medicines can help.

Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for MUSCLE SPASMS

MUSCLE SPASMS treatment research studies

Prednisone clinical trials, surveys and public health registries


Find Drug Side Effect reports



Prednisone Side Effects

Dyspnoea (309)
Pyrexia (283)
Nausea (273)
Pain (263)
Diarrhoea (255)
Arthralgia (247)
Fatigue (246)
Headache (234)
Pneumonia (231)
Pain In Extremity (210)
Asthenia (210)
Vomiting (205)
Dizziness (201)
Oedema Peripheral (198)
Weight Increased (187)
Weight Decreased (175)
Abdominal Pain (172)
Back Pain (169)
Condition Aggravated (161)
Anaemia (156)
Crohn's Disease (113)
Sepsis (110)
Osteonecrosis (105)
Dehydration (104)
Malaise (104)
Fall (101)
Insomnia (100)
Death (100)
Injection Site Pain (100)
Chest Pain (97)
Cough (96)
Confusional State (96)
Diabetes Mellitus (91)
Rash (89)
Blood Glucose Increased (88)
Anxiety (88)
Pulmonary Embolism (88)
Rheumatoid Arthritis (85)
Pruritus (83)
Hypertension (82)
Hypotension (80)
Depression (80)
Febrile Neutropenia (79)
Erythema (78)
Renal Failure (77)
Neutropenia (74)
Deep Vein Thrombosis (73)
Renal Failure Acute (71)
Hyperglycaemia (69)
Muscular Weakness (69)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

>:o :'(

3 weeks after i had been given 120m of predisone in a 24 hour period,i started getting dizzy spells severe enough that initially i blacked out while driving,needless to say i havent been driving my car,but i still am experiencing very bad dizzy spell

66 year old male. Good to excellent health. Non smoker, non drinker. Slowly deteriorated till all joints were swollen and eventually I became 99% immobile. Diagnosis? Spotless, Rocky Mountain Spotted Fever. (erlickiosis chaffnesis) Hospitalized, inf

Calf twitches

Calfs constly twitching

Female patient 39 taking prednisone for asthma. Prednisone 20 mg 4 days on and then one day off/one day onfor8 days. Menstrual type bleeding although not during menstrual period. Severe pelvic cramps and urgency of urination. Swol

I am asthmatic (since I was very little) 36yrs old, took 40mg Prednisone for 8 days - two days later I ovulated and then I started bleeding uncontrollably. Gynae said ovaries failed as blood work tested very low and put me on Duphaston to aid drying

I have been taking Metoprolol tar 25mg for the past six year my muscles have been hurting. If I set for a while its hard for me to get up and get moving. But Im in constant pain daily. It's been eight month since I stop taking them and im s

I have taken Prednisone for severe asthma on many occassions (including IV in hospital for 7 days) and suffered severe abdominal pain. Three years ago a gastroscopy revealed I had Duodenal ulcers and Gastritis, most likely caused from the Prednisilo

I just had my first shots of xolair 2wks ago. within the first few days I had some spasms in the right side of my back. i also exoerienced spasms in my left hand within those same few days. since then my left eye has been twitching every day.

<b><span style='font-weight: normal;'><b>After 6 weeks of oral lamisil I experienced</b>eczema, muscle weakness, asthma, bloody bowels, lower abdominal pain, dizziness, extreme f

muscle cramping when in a dead sleep

I just had the infusion two days ago (1/19/10) and was surprised with the intensity of muscle pain the day after the treatment. My pain was localized to my rib cage, neck, shoulders and upper back. In addition I was very fatiqued...slept most of

I started taking this medicine geodon 40 mg once a day. Then i notice i was blinking a lot. Then i started having eye muscle spasms several times a day.Now i have to go to the eye dr.I stop taking the medicine. Til I see what the dr.says.

I was having frequent leg cramps. They worked their way from my foot up to my thigh. I just thought it was from stopping the use of muscle relaxers ( for a serious back and neck problem). I had forgotten about them and never mentioned it to either

I am having cramps, muscle pain, memory loss, I have been on Revlmid for about 1 year. Does anybody else my age have this disease, I am only 46 yr woman.

one 10 mg pill cuased presure in thechest bad muslespasms in the back think past doses has sent me skizzo

<b>Describe Your Pravastatin Experience Here:</b> I have been on 20 mg since Jan. And have been having muscle pain in the back of the thighs? Has anyone felt muscle pain in that area. Don't know if it is from medication or exercise

I received an injection close to my shoulder blade June 16, 2010. Three months later, I have an indentation and my health care provider has indicated that perhaps the muscle has scare tissue and the indentation and disc

<span style='color: #808080;'><b>I experienced severe neck spasms the day after receiving my second shot of Gardasil. It's been 2 days with no releif. The doctor did not inform me of the side effects in fact she said '

MUSCLE SPASMS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
Condition: Multiple Myeloma
Interventions: Drug: velcade subcutaneous melphalan Prednisone;   Drug: velcade cyclophosphamide Prednisone;   Drug: velcade Prednisone
Outcome Measures: Very Good Partial Response, Complete response rate , Partial response rate;   Progression free survival;   Time to progression;   Time to Next Therapy;   Overall survival;   Time to response;   Duration of response;   Response rate
2 Recruiting The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
Conditions: Granulomatosis With Polyangiitis;   Wegener Granulomatosis;   Vasculitis
Interventions: Drug: 5 mg Prednisone;   Drug: 0 mg Prednisone
Outcome Measures: Prednisone dose increase for disease relapse;   Rates of disease flare sub types;   Time to event flare;   Health related quality of life;   Safety Outcomes;   Protocol performance
3 Recruiting The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach
Condition: Granulomatosis With Polyangiitis
Interventions: Drug: Prednisone 5 mg/day;   Drug: Prednisone 0 mg/day
Outcome Measures: Physician decision to increase glucocorticoids for disease relapse.;   Time to disease flare.;   Safety outcomes.;   Protocol performance at VCRC Centers of Excellence.;   Health-related quality of life survey;   Health-related quality of life surveys
4 Recruiting Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis
Condition: Cellulitis
Interventions: Drug: Prednisone;   Drug: Placebo
Outcome Measures: Change in VAS for pain - day 1 to 48 hours;   Change in erythema size - day 1 to 48 hours;   Amount of pain medication - day 1 to 48 hours;   Amount of pain medication - day 1 to 7 days;   Amount of pain medication - 48 hours to 7 days;   Additional Medical Assistance Post-Randomization;   Disposition Trend;   Adverse Events
5 Recruiting Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Bortezomib;   Drug: Melphalan;   Drug: Prednisone
Outcome Measures: Progression-Free Survival;   Overall Survival (OS);   Complete Response (CR) rate;   Overall Response Rate (ORR);   Change from baseline in health-related quality of life (HR-QOL) score
6 Recruiting Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
Condition: IgA Nephropathy
Interventions: Drug: Prednisone plus cyclophosphamide;   Drug: Prednisone alone
Outcome Measures: the changes of kidney function;   the changes of proteinuria
7 Recruiting Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)
Condition: Cholesterol Embolism Systemic
Interventions: Drug: Prednisone;   Other: placebo
Outcome Measures: 1-year survival and 1-year renal survival (composite criteria);   Number and duration of hospitalization(s);   course of renal function;   number of cardiovascular events;   Prednisone tolerance
8 Recruiting Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel, Reolysin and Prednisone;   Drug: Docetaxel and Prednisone
Outcome Measures: Disease Progression;   Effect of Docetaxel and Reolysin on circulating tumour cells;   PSA change rate;   Objective Response;   Overall Survival;   Determine patient tolerability and toxicity of Reolysin and Docetaxel in combination;   Prognostic/Predictive molecular response
9 Not yet recruiting Study of the Prednisone Sparing Effect of Xolair (Omalizumab) in Patients With Prednisone-dependent Asthma With Eosinophilic Bronchitis
Conditions: Prednisone Dependent Asthma;   Eosinophilic Bronchitis
Interventions: Biological: Omalizumab (Xolair);   Drug: Placebo
Outcome Measures: proportion of patients with exacerbations in each study group from week 0 to week 32.;   the magnitude of the reduction in the dose of Prednisone from week 12 to week 32.;   change in % sputum eosinophil;   Blood eosinophils;   Forced Expired Volume in 1 second (FEV1);   Ratio of Forced Expired Volume in 1 second to Forced Vital Capacity (FEV1/VC);   Provocative concentration causing a 20% drop in FEV1 (PC20);   Asthma Control Questionnaire;   Fraction of exhaled nitric oxide (FeNO)
10 Not yet recruiting Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: blinatumomab;   Drug: Prednisone;   Drug: vincristine sulfate;   Drug: methotrexate;   Drug: mercaptopurine;   Drug: dasatinib;   Other: laboratory biomarker analysis
Outcome Measures: Overall survival (OS) (Cohort I);   Incidence of dose-limiting toxicity, defined as any grade 3-4 non-hematologic toxicity in the first cycle of post-remission therapy (blinatumomab/dasatinib) (Cohort II);   Complete response (CR + CRi) rate (Cohort I);   Disease-free survival;   Response rates (Cohort II);   OS (Cohort II);   Incidence of toxicity graded according to National Cancer Institute CTCAE version 4.0;   MRD negativity;   Time to achieve MRD negativity
11 Recruiting Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer Metastatic
Interventions: Drug: CABAZITAXEL (XRP6258);   Drug: DOCETAXEL (XRP6976);   Drug: Prednisone
Outcome Measures: PSA response rate;   Circulating tumor cells (CTCs) with response to docetaxel or cabazitaxel treatment;   Progression-free survival;   PSA progression-free survival rate;   Objective response rate;   Radiographic progression-free survival (rPFS) rate;   Clinical progression-free survival (cPFS);   Overall survival
12 Recruiting Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy
Condition: Thyroid Associated Opthalmopathies
Interventions: Drug: Prednisone+placebo of Doxycycline;   Drug: Doxycycline+placebo of Prednisone
Outcome Measures: Overall treatment response;   • Health related quality of life questionnaires (GO-QoL);   • Safety and tolerability as assessed by adverse events, vital signs;   • Quantitative changes of rectus diameter measured by MRI scan;   Relapse
13 Recruiting A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Condition: Prostate Neoplasms
Interventions: Drug: Abiraterone acetate;   Drug: Prednisone;   Other: Androgen deprivation therapy (ADT);   Drug: Abiraterone acetate Placebo;   Drug: Prednisone Placebo
Outcome Measures: Overall Survival (OS);   Radiographic progression-free survival (PFS);   Time to next skeletal-related event;   Time to prostate specific antigen (PSA) progression;   Time to next subsequent therapy for prostate cancer;   Time to initiation of chemotherapy;   Time to Pain Progression
14 Recruiting Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Alisertib;   Drug: Abiraterone acetate;   Drug: Prednisone
Outcome Measures: Phase I: Frequency of dose limiting toxicities of Alisertib, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.1;   Phase II: Duration of progression free survival according to the PCWG2 criteria;   Change in PSA kinetics
15 Recruiting Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, Prednisone, custirsen sodium;   Drug: cabazitaxel, Prednisone
Outcome Measures: Survival;   Progression-free survival at Day 140
16 Recruiting Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: docetaxel;   Drug: pasireotide;   Drug: Prednisone
Outcome Measures: Occurrence of adverse events and the associated grade per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 to identify the maximum tolerated dose (MTD) of pasireotide in combination with docetaxel and Prednisone;   All specific types of toxicity as assessed via NCI CTCAE version 4.0;   Measurements of tumor using Response Evaluation Criteria In Solid Tumors (RECIST) criteria before and after treatment with the combination of pasireotide in combination with docetaxel;   Percentage prostate-specific antigen (PSA) decline noted;   Time to Progression (TTP);   Overall Survival (OS);   Pharmacokinetics (PK) parameters;   Measurement of levels of IGF-1, serum chromogranin A (SCA), and neuron specific enolase (NSE), pre-therapy, post-therapy, and the change between time points and association with duration of TTP and OS;   Measurements of CTC counts pre-therapy, post-therapy, and the change between time-points and association with duration of TTP and OS
17 Unknown  Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis
Condition: Focal Segmental Glomerulosclerosis
Interventions: Drug: Prednisone, FK506, MMF;   Drug: Prednisone
Outcome Measure: proteinuria,serum protein,Scr,blood routine examination,liver function test,blood glucose and lipid test
18 Recruiting Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Condition: Chronic GVHD
Interventions: Drug: Sirolimus + calcineurin inhibitor + Prednisone;   Drug: Sirolimus + Prednisone
Outcome Measures: Phase II: Proportion of subjects with CR/PR;   Phase III: Proportion of subjects with CR; resolution of GVHD manifestations;   Phase II: Avg. daily dose % reduction of Prednisone;   Phase II: Cumulative incidence of treatment failure;   Phase II: Prevalence of active symptomatic chronic GVHD;   Phase II: Incidence of discontinuation of all systemic immunosuppressive therapy;   Phase II: Overall and cancer progression-free survival;   Phase II: Serum biomarkers of chronic GVHD;   Phase III: Avg. daily dose % reduction of Prednisone;   Phase III: Cumulative incidence of treatment failure;   Phase III: Prevalence of active symptomatic chronic GVHD;   Phase III: Incidence of discontinuation of all systemic immunosuppressive therapy;   Phases III: Overall and cancer progression-free survival;   Phase III: Serum biomarkers of chronic GVHD
19 Unknown  Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial
Conditions: Idiopathic Retroperitoneal Fibrosis;   Perianeurysmal Retroperitoneal Fibrosis;   Chronic Periaortitis
Interventions: Drug: Methotrexate+Prednisone;   Drug: Prednisone
Outcome Measures: Remission rate by the end of treatment;   Reduction in size of the retroperitoneal mass on CT/MRI scans;   Rate of post-treatment relapses;   Treatment-related toxicity
20 Recruiting Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
Condition: Prostate Cancer
Interventions: Drug: Lupron;   Drug: Zoladex;   Drug: Degarelix;   Drug: Abiraterone Acetate;   Drug: Prednisone
Outcome Measure: Prostate Specific Antigen (PSA) Free Survival